Elizabeth A. Handorf

Fox Chase Cancer Center

Papers

1

Total Citations

10

H-Index

1

About

Elizabeth A. Handorf is a leading biostatistician whose research focuses on the intersection of statistical methodology and clinical decision-making in oncology, particularly for urologic cancers. Her major contributions include developing cost-effectiveness models and risk-stratification tools that directly inform treatment strategies for localized renal masses. In her widely cited 2021 work, "Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses," Handorf demonstrated how integrating biopsy into clinical pathways can optimize resource allocation while minimizing patient harm, a study that has garnered 10 citations and influenced guidelines for kidney cancer management. Beyond this, her broader portfolio encompasses survival analysis, comparative effectiveness research, and the application of advanced statistical techniques to large-scale cancer registry data. Her work has been instrumental in bridging the gap between complex biostatistical models and practical, patient-centered care. As a faculty member at Fox Chase Cancer Center, Handorf continues to shape the field by training the next generation of researchers in rigorous quantitative methods, ensuring that evidence-based medicine remains grounded in sound statistical reasoning.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses
10 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Fox Chase Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago